^
Association details:
Biomarker:No biomarker
Cancer:Diffuse Large B Cell Lymphoma
Regimen:GDP (cisplatin + dexamethasone injection + gemcitabine)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Published date:
01/20/2021
Excerpt:
Diffuse large B-Cell Lymphoma: SECOND-LINE AND SUBSEQUENT THERAPY…Preferred Regimens…GDP (gemcitabine, dexamethasone, cisplatin) ± rituximab or (gemcitabine, dexamethasone, carboplatin) ± rituximab